Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Arcus Biosciences, Inc. clinical trials
The registry lists 32 studies whose lead sponsor is Arcus Biosciences, Inc.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the Arcus Biosciences, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Arcus Biosciences, Inc..
- Arcus Biosciences, Inc.32 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 32 of 32.
- A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsRecruitingNCT05536141Phase 1
- Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaRecruitingNCT07011719Phase 3
- Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic FunctionRecruitingNCT07751250Phase 1
- A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy ParticipantsRecruitingNCT07662057Phase 1
- Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerCompletedNCT04736173Phase 2
- A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced MalignanciesCompletedNCT06120075Phase 1
- Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT06608927Phase 3
- A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesActive, not recruitingNCT05329766Phase 2
- Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersActive, not recruitingNCT05891171Phase 1
- A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal MalignanciesCompletedNCT04104672Phase 1
- A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyCompletedNCT05568095Phase 3
- A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult ParticipantsCompletedNCT07641881Phase 1
- Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerCompletedNCT04262856Phase 2
- Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)CompletedNCT07364214Phase 1
- Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)CompletedNCT06919991Phase 1
- An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.CompletedNCT04660812Phase 1/2
- A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesCompletedNCT04772989Phase 1
- Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerCompletedNCT04381832Phase 1/2
- A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced MalignanciesCompletedNCT03628677Phase 1
- A Study to Evaluate Immunotherapy Combinations in Participants With Lung CancerCompletedNCT03846310Phase 1
- A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult VolunteersCompletedNCT05999513Phase 1
- Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy VolunteersCompletedNCT05117554Phase 1
- Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid TumorsCompletedNCT04087018Phase 1
- A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy VolunteersCompletedNCT06004921Phase 1
- A Study to Investigate the Safety of AB680 in Healthy VolunteersCompletedNCT03677973Phase 1
- A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesCompletedNCT03719326Phase 1
- A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of CancerCompletedNCT05411146Phase 1
- A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult ParticipantsCompletedNCT05277012Phase 1
- A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult ParticipantsCompletedNCT05154136Phase 1
- A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesCompletedNCT03629756Phase 1
- A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal MalignanciesCompletedNCT03720678Phase 1
- A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy VolunteersCompletedNCT04575311Phase 1